Cancer Clinical Trial - Tolero TP-0903-101 RP

Status:

Open

ClinicalTrials.gov:

NCT02729298

CONDITION(S): Colorectal, Melanoma - TRIAL: Tolero TP-0903-101 RP - First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors

TP-0903 is a novel oral inhibitor that targets AXL kinase and reverses the mesenchymal phenotype associated with advanced cancers. Preclinical studies have shown promising antitumor activity of TP-0903 as a single agent against a variety of tumor types in both in vitro and in vivo studies.

Drug

TP-0903

Trial Type

Interventional

Condition

Colorectal cancer Melanoma

Keywords

Melanoma | Colorectal cancer